Search results for "Mucocutaneous Lymph Node Syndrome"

showing 10 items of 21 documents

Coronavirus disease 2019, Kawasaki disease, and multisystem inflammatory syndrome in children

2020

2019-20 coronavirus outbreakDelayed DiagnosisCoronavirus disease 2019 (COVID-19)Pneumonia ViralMucocutaneous Lymph Node Syndromemedicine.disease_causeDelayed diagnosisArticleBetacoronavirusPandemicmedicineHumansPediatrics Perinatology and Child HealthChildLetter to the EditorPandemicsCoronavirusbiologybusiness.industrySARS-CoV-2COVID-19biology.organism_classificationmedicine.diseaseVirologyMucocutaneous Lymph Node SyndromeCoronavirusPediatrics Perinatology and Child HealthKawasaki diseasebusinessCoronavirus InfectionsBetacoronavirusThe Journal of Pediatrics
researchProduct

Kawasaki disease epidemic: pitfalls

2020

AbstractRecent reports have described in the pediatric population a new type of hyperinflammatory response manifested following contact with SARS-CoV-2, with some of the clinical features attributable to Kawasaki disease (KD). The purpose of this commentary is to remark on a possible recent association between SARS-CoV-2 and KD. Although today little is known about the etiology of KD, the most accepted hypothesis is that of a probable viral etiology, therefore, even the SARS-CoV-2 virus could trigger, in genetically predisposed subjects, an exaggerated inflammatory response that is clinically evident like the one described in KD.

2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Inflammatory responsevirusesPneumonia ViralHyperinflammatory response; Kawasaki disease; Pediatric population; SARS-CoV-2; COVID-19; Coronavirus Infections; Humans; Mucocutaneous Lymph Node Syndrome; Pandemics; Pneumonia Viral; SARS-CoV-2; BetacoronavirusMucocutaneous Lymph Node SyndromeVirusBetacoronavirusSettore MED/38 - Pediatria Generale E SpecialisticaMedicineHumansPediatric populationViralskin and connective tissue diseasesPandemicsViral etiologyKawasaki diseasebusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsPneumoniamedicine.diseaseHyperinflammatory responseImmunologyEtiologyCommentaryKawasaki diseasebusinessCoronavirus InfectionsPediatric populationItalian Journal of Pediatrics
researchProduct

Revascularisation of a Giant Coronary Artery Aneurysm in Suspected Incomplete Kawasaki-Disease

2006

Kawasaki disease leads to typical vascular complications in up to 20 % of untreated cases. We describe a 47-year-old patient with coronary vessel disease, involving the right coronary artery with a huge aneurysmatic dilatation, suspicious for an incomplete form of Kawasaki disease. We found little information about the surgical treatment and postoperative course of this disease in adults. Typically, these infrequent patients present with acute myocardial infarction and require interdisciplinary decision-making.

Brain InfarctionPulmonary and Respiratory Medicinemedicine.medical_specialtyMyocardial InfarctionDiseaseMucocutaneous Lymph Node SyndromeCoronary AngiographyPostoperative ComplicationsAneurysmInternal medicinemedicine.arterymedicineHumanscardiovascular diseasesMyocardial infarctionCoronary Artery BypassSurgical treatmentCoronary artery aneurysmbusiness.industryCoronary ThrombosisCoronary AneurysmMiddle Agedmedicine.diseaseAortic DissectionIntracranial EmbolismRight coronary arteryCoronary vesselCardiologySurgeryKawasaki diseaseCardiology and Cardiovascular MedicinebusinessThe Thoracic and Cardiovascular Surgeon
researchProduct

Clostridium baratii bacteremia associated with Kawasaki syndrome. First case report

2007

We experienced a case of a 3-year-old boy who presented signs and symptoms of Kawasaki syndrome. Two blood culture sets were processed by the hospital microbiology laboratory using a standard blood culturing system. The anaerobic bottles gave a positive result at day 3 after inoculation. The biochemical profiles produced by the RapID ANA II System showed that the organism was Clostridium baratii with a probability of 99%. Our case highlights the importance of C. baratii as a potential human pathogen and reports the associations with manifestations, which, to our knowledge, have not been previously described concomitantly with a clostridial infection.

ClostridiumMaleBOTULISM TYPE-F; DISEASE; ADULT; INFECTIONS; HATHEWAYI; TOXINBacteremiaTOXINMucocutaneous Lymph Node SyndromeDISEASEAgarBOTULISM TYPE-FADULTINFECTIONSChild PreschoolHATHEWAYIClostridium InfectionsHumansAnaerobiosisReagent Kits Diagnostic
researchProduct

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in…

2021

Abstract Background There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clini…

Coronary artery abnormalities; Hypotension; Kawasaki disease; Multisystem inflammatory syndrome associated with coronavirus disease; Myocarditis; Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; COVID-19; Child; Child Preschool; Coronary Artery Disease; Cough; Diarrhea; Dyspnea; Female; Glucocorticoids; Heart Failure; Humans; Hyperferritinemia; Hypotension; Immunoglobulins Intravenous; Immunologic Factors; Infant; Intensive Care Units Pediatric; Interleukin 1 Receptor Antagonist Protein; Italy; Lymphopenia; Male; Mucocutaneous Lymph Node Syndrome; Myocarditis; Platelet Aggregation Inhibitors; SARS-CoV-2; Shock; Systemic Inflammatory Response Syndrome; Tachypnea; Troponin T; VomitingMalelcsh:Diseases of the musculoskeletal systemcoronary artery abnormalities; hypotension; kawasaki disease; multisystem inflammatory syndrome associated with coronavirus disease; myocarditis; pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; age distribution; antirheumatic agents; aspirin; C-reactive protein; COVID-19; child ; preschool; coronary artery disease; cough; diarrhea; yspnea; female; glucocorticoids; heart failure; humans; hyperferritinemia; hypotension; immunoglobulins; intravenous; immunologic factors; infant; intensive care units; pediatric; interleukin 1 receptor antagonist protein; italy; lymphopenia; male; mucocutaneous lymph node syndrome; myocarditis; platelet aggregation inhibitors; SARS-CoV-2; shock; systemic inflammatory response syndrome; tachypnea; troponin T; vomitingMyocarditiCoronary Artery Disease030204 cardiovascular system & hematologySARS-CoV-2 Kawasaki disease Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection Myocarditis Hypotension Multisystem inflammatory syndrome associated with coronavirus disease Coronary artery abnormalitiesCoronary artery diseaseSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineGlucocorticoidImmunologic FactorMultisystem inflammatory syndrome associated with coronavirus diseaseImmunology and AllergyChildCoronary artery abnormalitieFisher's exact testPediatricTachypneabiologylcsh:RJ1-570Antirheumatic AgentImmunoglobulins IntravenousShockPediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infectionSettore MED/38Systemic Inflammatory Response SyndromeIntensive Care UnitsMyocarditisC-Reactive ProteinItalyAntirheumatic AgentsChild PreschoolCohortsymbolsPlatelet aggregation inhibitorFemaleHypotensionIntravenousCoronary artery abnormalitiesHumanResearch ArticleDiarrheamedicine.medical_specialtyMyocarditisVomitingImmunoglobulinsMucocutaneous Lymph Node SyndromeIntensive Care Units Pediatric03 medical and health sciencessymbols.namesakeAge DistributionRheumatologyTroponin TInternal medicineLymphopeniamedicineHumansImmunologic FactorsPreschoolGlucocorticoids030203 arthritis & rheumatologyHeart FailureAspirinKawasaki diseasebusiness.industrySARS-CoV-2Platelet Aggregation InhibitorC-reactive proteinCOVID-19Infantlcsh:Pediatricsmedicine.diseaseSystemic inflammatory response syndromeInterleukin 1 Receptor Antagonist ProteinDyspneaCoughImmunoglobulins IntravenouPediatrics Perinatology and Child Healthbiology.proteinKawasaki diseaseHyperferritinemialcsh:RC925-935businessPlatelet Aggregation InhibitorsPediatric rheumatology online journal
researchProduct

Intestinal Involvement in Kawasaki Disease

2018

Objectives To describe a case of Kawasaki disease with intestinal involvement and to analyze other published reports to define clinical characteristics, diagnostic issues, and therapeutic approaches of gastrointestinal involvement in Kawasaki disease. Study design A computerized search without language restriction was conducted using PubMed and SCOPUS. An article was considered eligible for inclusion in the systematic review if it reported data on patient(s) with intestinal involvement in Kawasaki disease. Our case was also included in the analysis. Results Thirty-three articles reporting 48 cases of Kawasaki disease with intestinal involvement were considered. Fever, abdominal pain, and vo…

Intestinal pseudo-obstructionMalemedicine.medical_specialtyPediatricsAbdominal painSettore MED/17 - Malattie InfettiveAdolescentFeverMucocutaneous Lymph Node SyndromeDiagnosis Differential03 medical and health sciences0302 clinical medicinepediatric gastroenterology030225 pediatricsmedicineintestinal pseudo-obstructionHumans030212 general & internal medicineHematologic TestPediatric gastroenterologyCoronary artery aneurysmGangreneAspirinHematologic TestsIntestinal Diseasebusiness.industryabdominal painImmunoglobulins Intravenousmedicine.diseasecoronary artery aneurysmHospitalizationIntestinal DiseasesImmunoglobulins IntravenouPediatrics Perinatology and Child HealthKawasakiSplenomegalyVomitingKawasaki diseasemedicine.symptombusinessTomography X-Ray ComputedBowel diseaseIntestinal Obstructionmedicine.drugHepatomegalyHuman
researchProduct

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct

Kawasaki disease triggered by EBV virus in a child with Familial Mediterranean Fever

2019

Abstract Background Familial Mediterranean Fever is a monogenic autoinflammatory disease, secondary to mutation of MEFV gene, and typically expressed with recurrent attacks of fever, serositis, rash, aphthous changes in lips and/or oral mucosa. Kawasaki Disease, an acute systemic vasculitis with persistent fever (5 or more days), rash, stomatitis, conjunctivitis, lymphadenopathy, changes in extremities, is currently considered a multifactorial autoinflammatory disease. An infection, as Epstein Barr virus, can be the trigger of Kawasaki Disease. Case presentation We describe the clinical case of a 3-year-old boy with Kawasaki disease. Successfully treated with intravenous immune globulin, ac…

Male0301 basic medicineEpstein-Barr Virus InfectionsFamilial Mediterranean feverCase ReportMucocutaneous Lymph Node SyndromeFamilial Mediterranean fever03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicinehemic and lymphatic diseasesmedicineHumansskin and connective tissue diseasesEpstein–Barr virus infectionKawasaki diseasebusiness.industrylcsh:RJ1-570Epstein Barr viruslcsh:Pediatricsmedicine.diseaseMEFVRashPharyngitis030104 developmental biologyChild PreschoolEpstein Barr viruImmunologyKawasaki diseasemedicine.symptombusinessSerositis030217 neurology & neurosurgerySystemic vasculitisItalian Journal of Pediatrics
researchProduct

Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, li…

2018

Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.

MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studies
researchProduct

Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and manag…

2018

Abstract The primary purpose of these practical guidelines related to Kawasaki disease (KD) is to contribute to prompt diagnosis and appropriate treatment on the basis of different specialists’ contributions in the field. A set of 40 recommendations is provided, divided in two parts: the first describes the definition of KD, its epidemiology, etiopathogenetic hints, presentation, clinical course and general management, including treatment of the acute phase, through specific 23 recommendations. Their application is aimed at improving the rate of treatment with intravenous immunoglobulin and the overall potential development of coronary artery abnormalities in KD. Guidelines, however, should…

MalePediatricsReviewPediatricsSeverity of Illness Index0302 clinical medicineRetrospective StudieEpidemiology030212 general & internal medicineDisease management (health)Coronary artery abnormalitieChildrenSocieties MedicalRandomized Controlled Trials as TopicPediatriclcsh:RJ1-570Disease ManagementImmunoglobulins IntravenousGeneral MedicinePrognosisSettore MED/38Treatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMeta-analysisAcute DiseasePractice Guidelines as TopicDisease ProgressionFemaleCoronary artery abnormalitiesAspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki disease;Humanmedicine.medical_specialtyPrognosiMucocutaneous Lymph Node SyndromeRisk Assessment03 medical and health sciences030225 pediatricsSeverity of illnessmedicineHumansRisk factorIntravenous immunoglobulinRetrospective Studiesaspirin; children; coronary artery abnormalities; intravenous immunoglobulin; Kawasaki disease; pediatrics perinatology and child healthAspirinKawasaki diseasebusiness.industrylcsh:PediatricsRetrospective cohort studymedicine.diseaseImmunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseDifferential diagnosisbusiness
researchProduct